PODCAST

Targeted Therapies: A Paradigm Shift in RCC

Interviewed by Ron Piana | June 8, 2010

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.

Dr. Motzer has led more than 50 clinical trials in patients with kidney cancer and testicular cancer, including national and international multicenter clinical studies. His research has helped identify three targeted antiangiogenesis drugs -- sunitinib (Sutent), temsirolimus (Torisel), and everolimus (Afinitor), as effective first- or second-line treatments for patients with advanced kidney cancer.

Robert J. Motzer, MD

AUDIO:

Right-click to download MP3

Robert J. Motzer, MD

AUDIO:

Right-click to download MP3

Coming up: Dr. Motzer gives his expert perspective on ASCO sessions and abstracts focusing on renal cell carcinoma…also watch for coverage highlights in gastrointestinal cancers, both colorectal and non-colorectal cancers, and special guest Editor Samuel M. Silver, MD, PhD, highlighting sessions on hematological malignancies.

by Gregory Pawelski | December 22, 2010 9:35 AM EST

In cancer medicine, it's not a case of throwing targeted drugs at the problem, it's knowing "what"targeted drugs and "how" to use them in "individual patients (not average populations).

The barrier to entry (FDA approval) is much lower in renal cell cancer with numerous targeted therapies now approved for a relatively small niche indication, including Nexavar (sorafenib), Sutent (sunitinib), Torisel (temsirolimus), Afinitor (everolimus), Votrient (pazopanib) and Avastin (bevacizumab).

Scientists involved with "real time" cell function analysis, which simultaneously measures direct antitumor activity and antivascular activity, prospectively, on fresh "live" human cancer cells, have found that Avastin may facilitate vascular access of Torisel (temsirolimus).

There are so many excellent agents for renal cell cancer (a bad actor type of cancer, when advanced), but with mass confusion for oncologists in knowing how to use them, cell-based funcitonal profiling can be very helpful.

by carlos Zeckler | November 23, 2010 12:58 AM EST

Financial Information?
Please editors of Cancernetwork.com, if you are going to publish comments and therapy dialogue with a respected Md, Robert J. Motzer, MD, PUBLISH CLEARLY THE FINANCIAL RELATIONSHIPS WITH THE MD and any drug companies!
I do not see any disclosures in the article, and as a matter of transparency, this is a critical disclosure. Does the Md receive(d) any form of compensation the makers of the drugs being discussed/ recommended by Dr Motzer?

Transparency and clarity of the presenters is vital in analyzing the information given, just as it would be if this were a financial broker discussing and recommending particular stock? Agreed?

ASCO 2010 Renal Cell Carcinoma

ASCO 2010: Selected Sessions in Renal Cell Carcinoma

Targeted Therapies: A Paradigm Shift in RCC

New Generation of Targeted Therapies Show Promise in RCC

At Increased Cost, Robotic Partial Nephrectomy Improves Kidney Cancer Outcomes
May 7, 2013

FDA Panel Votes 'No' on Tivozanib for Renal Cancer
May 3, 2013

Small Kidney Tumors Potentially Dangerous, Worth Treating
April 19, 2013

Serum Assay Composed of Trio of Biomarkers May Help Detect Kidney Cancers
April 18, 2013

TOPIC INDEX

Cancer Types
Breast Breast (HER2+) Breast (Triple-Negative) CML Colorectal Gastrointestinal GIST Genitourinary Gynecologic Head & Neck	Hematology Kidney (Renal Cell) Leukemia Lung Lymphoma Melanoma Multiple Myeloma Ovarian Prostate Sarcoma
Supportive Care	More Topics
Bone Metastases End-of-Life Care Palliative Care	Ethics in Oncology Practice Management Practice & Policy

All Topics

SEARCH MEDICA RX

Browse drugs by name:

All

Search for drugs:

FROM PHYSICIANS PRACTICE

Five Steps to Improving Patient Access
Judy Capko, May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.

Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins, May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.

Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD, May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.

Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz, May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.

Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD, May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.

Targeted Therapies: A Paradigm Shift in RCC

Join the Conversation